Jade Biosciences plans to start the Phase 3 trial of Jade 101 in IgA nephropathy this quarter, before Phase 2 data arrives in the second quarter of next year. It says Phase 2 data won't inform Phase 3 design.
JBIO · Jade Biosciences, Inc.
The latest filing no longer states the doubt (first flagged Aug 10, 2026).
View the 10-Q filed Nov 13, 2026You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 81%
- Last earnings
- Mar 10, 2026
- Latest filing
- 10-Q · Nov 13
- Price history
- Jun 2021 to Nov 2026
Latest documents
Jade Biosciences aims to initiate a phase three trial this quarter, read out Jade 101 Phase 2 data in Q2-2027, and plans three readouts in 2027.
Jade Biosciences plans to initiate the JADE101 EVERGREEN Phase 3 trial in the fourth quarter of 2026. Net loss was $35.1 million for three months and $131.2 million for nine months ended September 30, 2026, while cash and investments totaled $475.7 million.
Jade Biosciences reported $475.7 million in cash, cash equivalents and investments as of September 30, 2026, expected to fund operations into the fourth quarter of 2028. The EVERGREEN Phase 3 trial is expected to begin in the fourth quarter of 2026.
Jade Biosciences plans to begin a Phase III for Jade 101 in IGA nephropathy this quarter, with Phase II interim results in the second quarter of 2027; Phase I showed around 70 percent reduction in IgA at the 700 milligram dose.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JBIO
this stock
Jade Biosciences, Inc.
|
$1.06B | -0.8% | — | — | 15.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 31
Jade Biosciences plans to start the Phase 3 trial of Jade 101 in IgA nephropathy this quarter, before Phase 2 data arrives in the second quarter of next year. It says Phase 2 data won't inform Phase 3 design.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JBIO | -5.1% | +4.9% | -13.8% | +8.9% | -0.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +3.4% | +14.2% | -4.6% | +17.6% | -1.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.